The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Index—Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?
F. Porpiglia(Hospital de Galdakao), Daniele Regge(Candiolo Cancer Institute), Enrico Bollito(Prostate Cancer UK), Cristian Fiori(University of Turin), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), F. Mele(University of Turin), Matteo Manfredi(Ospedale San Luigi Gonzaga), Filippo Russo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Mauro Papotti(University of Turin), Ivan Molineris(University of Turin)
Cited by 71
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
|Leukemia|2013|305
Supine Valdivia and modified lithotomy position for simultaneous anterograde and retrograde endourological access
|British Journal of Urology|2007|288